Last A$1.17 AUD
Change Today +0.07 / 6.36%
Volume 351.5K
BLT On Other Exchanges
As of 2:10 AM 09/2/14 All times are local (Market data is delayed by at least 15 minutes).

benitec biopharma ltd (BLT) Snapshot

Previous Close
Day High
Day Low
52 Week High
02/25/14 - A$2.38
52 Week Low
09/4/13 - A$0.28
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for BENITEC BIOPHARMA LTD (BLT)

Related News

No related news articles were found.

benitec biopharma ltd (BLT) Related Businessweek News

No Related Businessweek News Found

benitec biopharma ltd (BLT) Details

Benitec Biopharma Limited, a biotechnology company, develops novel treatments for chronic and life-threatening conditions based on its gene silencing technology, DNA-directed RNA interference (ddRNAi). The company’s ddRNAi technology provides novel therapeutics to treat a range of human medical diseases and conditions, such as hepatitis C, hepatitis B, wet age-related macular degeneration, cancer-associated pain, drug resistant lung cancer, and oculopharyngeal muscular dystrophy (OPMD). Its pipeline of in-house and partnered therapeutic programs include TT-034 for hepatitis C; Tribetarna for the treatment of chemotherapy resistant non-small cell lung cancer; Hepbarna for Hepatitis B; and Pabparna for the treatment of OPMD. The company also licenses its ddRNAi technology to biopharmaceutical companies for the clinical applications comprising HIV/AIDS, retinitis pigmentosa, and Huntington’s disease. Benitec Biopharma Limited was founded in 1997 and is based in Sydney, Australia.

13 Employees
Last Reported Date: 08/22/14
Founded in 1997

benitec biopharma ltd (BLT) Top Compensated Officers

Chief Executive Officer, Managing Director an...
Total Annual Compensation: A$450.0K
Chief Financial Officer and Company Secretary
Total Annual Compensation: A$267.4K
Chief Business Officer
Total Annual Compensation: A$302.0K
Senior Vice President of Research and Develop...
Total Annual Compensation: A$305.1K
Chief Scientific Officer
Total Annual Compensation: A$225.0K
Compensation as of Fiscal Year 2014.

benitec biopharma ltd (BLT) Key Developments

Benitec Biopharma Limited Provides Guidance on Clinical Trial Updates

Benitec Biopharma Limited provided guidance regarding the anticipated schedule of reporting of its 'first in man' Phase l/lla clinical trial for TT-034, a ddRNAi- based therapeutic designed to treat and potentially cure hepatitis C (HCV) with a single treatment. The clinical trial protocol for TT-034 calls for an independent expert panel (called the Data Safety Monitoring Board (DSMB)) to carefully assess the data from the first patient data six weeks after dosing and determine whether it is then safe to dose the second patient. The clinical trial protocol for TT-034 provides for five cohorts, with each cohort containing either two (for cohort 1) or three (for cohorts 2-5) patients. Each cohort represents a different dose level and the dose level will ascend as the trial progresses. In cohorts 2-5, a single patient will be dosed and a DSMB review will occur at a specified time post dosing. As with cohort 1, each patient in subsequent cohorts will be monitored and an additional DSMB assessment will determine if it is safe to proceed to the next higher dose level.

Benitec Biopharma Limited Presents at 2014 Bioshares Biotech Summit, Jul-18-2014 through Jul-19-2014

Benitec Biopharma Limited Presents at 2014 Bioshares Biotech Summit, Jul-18-2014 through Jul-19-2014. Venue: Rydges Lakeland Resort, Queenstown, New Zealand. Presentation Date & Speakers: Jul-19-2014, Peter French, Chief Executive Officer, Managing Director and Director.

Benitec Biopharma Limited Accepts the Melvyn Bridges as Nonexecutive Director

Benitec Biopharma Limited accepted the resignation of nonexecutive Director, Dr. Melvyn Bridges. Dr. Bridges has served on the Board since October 2007.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BLT:AU A$1.17 AUD +0.07

BLT Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Galena Biopharma Inc $2.29 USD -0.067
Marina Biotech Inc $1.04 USD -0.05
Prosensa Holding NV $9.35 USD +0.25
Regulus Therapeutics Inc $6.90 USD +0.02
Silence Therapeutics PLC 211.75 GBp +0.25
View Industry Companies

Industry Analysis


Industry Average

Valuation BLT Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 86.0x
Price/Book 4.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales 74.3x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BENITEC BIOPHARMA LTD, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at